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Introduction: This paper presents three probable cases of pneumocystis pneumonia in patients receiving
bortezomib therapy for multiple myeloma.
Presentation of cases: Three patients receiving bortezomib therapy for multiple myeloma presented with
dyspnoea, non-productive cough, and fevers. These patients deteriorated despite receiving broad-
spectrum antibiotic therapy with piperacillin + tazobactam and azithromycin and an assortment of
other antimicrobials but promptly responded to sulfamethoxazole + trimethoprim therapy. Only one of
the patients exhibited a positive Pneumocystis jirovecii PCR test but testing was sub-optimal.
Discussion: Although only one of the patients exhibited a positive sputum P. jirovecii PCR test, the
diagnosis of PCP in these three patients is supported by their; clinical and radiological features consistent
with PCP, deterioration despite receiving broad-spectrum antibiotic therapy, and prompt responses to
sulfamethoxazole + trimethoprim therapy. In the patients with negative P. jirovecii PCR bronchoalveolar
lavage specimens were not obtained as these patients were deemed too high risk to undergo the
procedure. Although the three patients were also receiving dexamethasone therapy, the doses and
durations were at the threshold of those expected to cause PCP.
Conclusion: 26S proteosome inhibitor therapy for multiple myeloma may be a risk factor for PCP and
clinicians should adopt a high level of suspicion for PCP in patients receiving these medications until
conclusive evidence is obtained.
Crown Copyright  2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Pneumocystis jirovecii is an airborne fungus which exclusively
colonises the respiratory tract of humans. In immunocompromised
individuals it may cause pneumocystis pneumonia (PCP), which
typically exhibits an insidious course in HIV-infected individuals
and a more fulminant course in non-HIV-infected individuals [1–
8]. P. jirovecii polymerase chain reaction of bronchoalveolar lavage
(BAL) specimens is the current gold standard diagnostic test for
PCP in these patients [9]. Bortezomib is a reversible mammalian
26S proteosome inhibitor used for remission induction and
maintenance in multiple myeloma. It has been implicated in
several cases of pulmonary disease and one case of PCP has been* Corresponding author at: The Wollongong Hospital, Locked Mail Bag 8808,
South Coast Mail Centre, NSW 2500, Australia. Tel.: +61 2 4222 5898;
fax: +61 2 4222 5367.
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3.0/).reported [10–12]. This paper presents three probable cases of PCP
in patients receiving bortezomib therapy.
Presentation of cases
Written informed consent was obtained from the patient or, in
cases where the patient did not have the capacity to give informed
consent, from their next of kin for publication of this case series.
A copy of the written consent is available for review by the Editor-
in-Chief of this journal on request.
Case 1
A 76-year-old male with multiple myeloma presented with
malaise, confusion, pleuritic chest pain, dyspnoea, non-produc-
tive cough, and fevers for ten days. His past medical history
included; type 2 diabetes mellitus, iatrogenic primary adrenal
insufﬁciency, Parkinson disease, ischaemic heart disease, and
non-melanoma skin cancers. Fourteen days previously, he
had commenced his ﬁrst cycle of cyclophosphamide 500 mgcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. CT chest demonstrating left and right upper lung lobe ground-glass
inﬁltration.
Fig. 2. CT chest demonstrating left and right lower lung lobe extensive interstitial
ﬁbrotic changes with honey-combing.
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methasone 20 mg orally on days one, eight, and 15. He had
previously been receiving prednisone 10 mg orally daily for his
adrenal insufﬁciency. The patient’s vital signs were within
normal ranges. He was emaciated. Coarse inspiratory crepita-
tions were auscultated over the left and right lower lung zones.
A full blood count (FBC) demonstrated a white cell count (WCC)
of 3.44  109/L and a neutrophil count of 2.0  109/L and a
lymphocyte count of 1.0  109/L, a blood haemoglobin concen-
tration (HbC) of 104 g/L, and a platelet count (PtC) of 74  109/L.
The serum C-reactive protein (CRP) concentration was 123 mg/L.
Serum protein electrophoresis and immunoﬁxation demonstrat-
ed hypergammaglobulinaemia with an IgG kappa paraprotein.
The serum electrolytes, urea, creatinine (EUC), calcium, magne-
sium, and phosphate (CMP) concentrations, liver function tests
(LFT), and coagulation studies were within normal ranges. A
chest radiograph demonstrated reticular middle and lower lung
zone opacities bilaterally. A chest computed tomography scan
(CT) demonstrated left and right lower lung lobe patchy
consolidation and left and right upper lung lobe ground-glass
inﬁltration (Fig. 1). Two blood culture sets demonstrated nil
growth. Chlamydia pneumoniae and Mycoplasma pneumoniae
serology and urine Legionella and Pneumococcal antigen tests
were negative. After receiving benzylpenicillin 1.2 g intrave-
nously every 6 h and doxycycline 100 mg orally every 12 h for
two days, the patient did not improve clinically. The antimicro-
bial regimen was changed to piperacillin + tazobactam 4
g + 0.5 g intravenously every 8 h and azithromycin 500 mg
intravenously every 24 h. He was also transfused with two
units of packed red blood cells. Five days later he continued to
exhibit hypoxaemia with a SpO2 of 88% on room air and fevers
of 37.8 8C. The antibiotic regimen was again changed to
sulfamethoxazole + trimethoprim 1600 + 320 mg orally every
8 h. An expectorated sputum specimen obtained one day later
exhibited a negative P. jirovecii b-tubulin real-time polymerase
chain reaction (qPCR) test. BAL specimens could not be obtained
as the patient’s respiratory failure and frailty precluded
bronchoscopy. P. jirovecii microscopy was not ordered. Over
the following ﬁve days the patient improved clinically and his
serum CRP concentration normalised. He continued oral
sulfamethoxazole + trimethoprim to complete a total of 21 days
of therapy.Case 2
A 55-year-old female with multiple myeloma presented with
malaise, dyspnoea, non-productive cough, and fevers for two
days. Her past medical history included; chronic obstructive
pulmonary disease, hypertension, gastro-oesophageal reﬂux
disease, recurrent herpes zoster, non-melanoma skin cancers,
major depressive disorder, and appendicectomy. Eighteen days
previously, she had commenced her third cycle of doxorubicin
28 mg orally on days one and four and bortezomib 1.8 mg
subcutaneously and dexamethasone 20 mg orally on days one,
four, eight, and 11. She was tachycardic at 137 beats per minute
and febrile at 37.7 8C but neither hypotensive nor hypoxaemic.
Coarse inspiratory crepitations were auscultated over the left
and right lower lung zones. A FBC demonstrated a WCC of
3.13  109/L and a neutrophil count of 1.9  109/L and a
lymphocyte count of 0.7  109/L, a HbC of 100 g/L, and a PtC
of 519  109/L. Serum protein electrophoresis and immunoﬁxa-
tion demonstrated hypogammaglobulinaemia with an IgA
lambda paraprotein. The serum IgG, IgA, and IgM concentrations
were 3.02 g/L, 0.59 g/L, and 0.51 g/L respectively. EUC, CMP, LFT,
and coagulation studies were within normal ranges. The serum
CRP concentration was 140 mg/L. A chest radiograph demon-
strated reticular opacities within the right middle and lower and
left lower lung zones. A chest CT demonstrated left and right
lower lung lobe extensive interstitial ﬁbrotic changes with
honey-combing (Fig. 2). Three blood culture sets demonstrated
nil growth. C. pneumoniae and M. pneumoniae serology and urine
Legionella and Pneumococcal antigen tests were negative. After
receiving piperacillin + tazobactam 4 + 0.5 g intravenously every
8 h and azithromycin 500 mg intravenously every 24 h for three
days the patient did not improve and exhibited a SpO2 of 80% and
a PaO2 of 59.7 mmHg whilst receiving oxygen at a rate of 15 L/
min via non-rebreather mask and a fever of 39.1 8C. An
expectorated sputum specimen exhibited a negative P. jirovecii
immunoﬂuorescence test but a positive b-tubulin qPCR test. The
antibiotic regimen was changed to sulfamethoxazole + trimetho-
prim 1200 + 240 mg intravenously every 8 h. After ﬁve days the
patient improved clinically and her serum CRP concentration
normalised. She continued sulfamethoxazole + trimethoprim
800 + 160 mg orally every 6 h to complete a total of 21 days of
therapy.
Fig. 3. CT chest demonstrating diffuse airspace consolidation and small pleural
effusions bilaterally.
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A 74-year-old male with multiple myeloma presented with
dyspnoea, non-productive cough, right-sided pleuritic chest pain,
and fevers for one day. His medical history also included; gastro-
oesophageal reﬂux disease, peptic ulcer disease, recurrent herpes
zoster, gout, glaucoma, and inguinal hernia repair. Nine days
previously, he had commenced his fourth cycle of cyclophospha-
mide 500 mg intravenously on day one and bortezomib 2.2 mg
subcutaneously and dexamethasone 20 mg orally on days one,
four, eight, and 11. He was tachycardic at 110 beats per minute,
hypotensive at 86/53 mmHg, tachypnoeic at 26 breaths per
minute, hypoxaemic with a SpO2 of 93% and a PaO2 of 63.5 mmHg
whilst receiving oxygen at a rate of 15 L/min via non-rebreather
mask, and febrile at 38.5 8C. Bronchial breath sounds and coarse
inspiratory crepitations were auscultated throughout the lung
zones bilaterally. A FBC demonstrated a WCC of 15.83  109/L and
a neutrophil count of 11.3  109/L and a lymphocyte count of
0.7  109/L, a HbC of 138 g/L, and a PtC of 190  109/L. The serum
CRP concentration was 114 mg/L. Serum protein electrophoresis
and immunoﬁxation demonstrated an IgA lambda paraprotein.
The serum IgG, IgA, and IgM concentrations were 2.36 g/L, 0.50 g/L,
and 0.24 g/L respectively. EUC, CMP, LFT, and coagulation studies
were within normal ranges. A chest radiograph and a CT chest
demonstrated diffuse airspace consolidation and small pleural
effusions bilaterally (Fig. 3). He was admitted to the high
dependency unit and commenced continuous positive airway
pressure ventilation via high ﬂow nasal prongs and piperacil-
lin + tazobactam 4 + 0.5 g intravenously every 8 h, azithromycin
500 mg intravenously every 12 h, vancomycin 1.5 g intravenously
every 12 h, and oseltamivir 75 mg orally every 12 h. Three sets of
blood cultures also demonstrated nil growth. C. pneumoniae,
Bordetella pertussis, M. pneumoniae, and Inﬂuenza virus serology
and urine Legionella and Pneumococcal antigen tests were
negative. Inﬂuenza virus, respiratory syncytial virus, adenovirus,
and parainﬂuenza virus nasopharyngeal aspirate immunoﬂuores-
cence tests were negative. After three days there was no
improvement clinically and the serum CRP concentration in-
creased to 281 mg/L. He commenced sulfamethoxazole + tri-
methoprim 1200 + 400 mg intravenously every 8 h and
prednisone 40 mg orally every 12 h and received 60 g of
intravenous immunoglobulin. An induced sputum specimen
obtained one day later demonstrated light growth of upperrespiratory tract ﬂora and mixed Candida species on culture and
negative P. jirovecii immunoﬂuorescence and b-tubulin qPCR test
tests. BAL specimens could not be obtained as the patient’s
respiratory failure and septic shock precluded bronchoscopy. After
four days, the patient improved clinically and the blood WCC and
serum CRP concentration normalised. He was discharged to home
ﬁve days later and continued sulfamethoxazole + trimethoprim
1600 + 320 mg orally every 8 h to complete a total of 21 days of
therapy.
Discussion
Although a positive P. jirovecii sputum PCR test result was only
obtained in case 2, the clinical and radiological features observed in
all three cases were consistent with PCP. All three cases
deteriorated despite receiving broad-spectrum antibiotic therapy
with piperacillin + tazobactam and azithromycin and an assort-
ment of other antimicrobials, suggesting the presence of a
pathogen resistant to these agents. Although pneumonia due to
Toxoplasmosis gondii and viruses may be clinically and radiologi-
cally indistinguishable from PCP, it was thought that PCP was the
most likely diagnosis. All three cases responded promptly to
sulfamethoxazole + trimethoprim therapy.
The paucity of investigation results supporting the diagnosis of
PCP in these cases may be attributed to the lack of appropriate
investigations. No investigations for the identiﬁcation of P. jirovecii
were performed prior to the commencement of sulfamethoxazo-
le + trimethoprim therapy in cases 1 and 3. Furthermore,
expectorated and induced sputum specimens were tested in all
three cases because the high risk of respiratory deterioration
precluded bronchoscopy to obtain BAL specimens. P. jirovecii PCR
testing of induced sputum specimens exhibits a sensitivity of 78.9%
and a speciﬁcity of 89.0% compared with BAL specimens in HIV-
infected individuals [13]. The lower fungal burden of non-HIV-
infected individuals with PCP compared with HIV-infected
individuals may also have contributed to the lack of evidence to
conﬁrm the diagnosis of PCP in cases 1 and 3 [14,15].
All three cases received oral dexamethasone therapy at doses
which may precipitate PCP, so these cases cannot be directly
attributed to treatment with bortezomib. However, the doses of
dexamethasone therapy in all three cases were at the threshold of
those expected to cause PCP, equivalent to 20 mg of prednisone
daily for greater than four weeks [16,17].
A review of the literature identiﬁed one reported case of PCP
caused by bortezomib [13] and no reported cases of PCP caused by
carﬁlzomib, a second generation 26S proteosome inhibitor. Both
agents inhibit the chymotrypsin-like activity of the mammalian
26S proteosome, thereby preventing proteolysis of ubiquitinated
proteins and causing activation of signalling cascades, cell-cycle
arrest, and apoptosis [18]. As P. jirovecii is an obligate intracellular
fungus, it is possible that failure of host cell apoptosis may
facilitate its reproduction and transition from respiratory tract
coloniser to pathogen. Furthermore, all three cases exhibited
lymphopaenia, which may have predisposed them to developing
PCP. Patients receiving bortezomib or carﬁlzomib therapy for
multiple myeloma also exhibit a higher incidence of herpes zoster
compared with those receiving dexamethasone therapy, but there
does not appear to be any correlation with the lymphocyte count
[19–21], suggesting that 26S proteosome inhibitors may also
predispose to opportunistic infections by impeding lymphocyte
function.
In non-HIV-infected individuals, PCP exhibits a mortality rate of
90–100% in the absence of appropriate treatment [22] whilst PCP
associated with acute respiratory failure, as observed in the
three cases described in this series, exhibits a mortality rate of up
to 67% despite appropriate treatment [23]. Guidelines have been
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le + trimethoprim in patients with cancer [24] and a meta-analysis
of 12 randomised controlled trials with 1245 non-HIV-infected
patients with immunocompromise observed a 91% relative risk
reduction and a number needed to treat of 15 for sulfamethox-
azole + trimethoprim PCP prophylaxis with an incidence of adverse
effects warranting prophylaxis cessation of 3.1% [25]. There is
currently insufﬁcient evidence to support the use of PCP
prophylaxis in patients receiving 26S proteosome inhibitor
therapy for multiple myeloma. However, in the event that further
surveillance conﬁrms the existence of an association between PCP
and 26S proteosome inhibitor therapy, PCP prophylaxis may be
indicated in these patients.
Conclusion
26S proteosome inhibitor therapy for multiple myeloma may
be a risk factor for Pneumocystis jirovecii pneumonia. Clinicians
should adopt a high level of suspicion for PCP and may consider
lowering the threshold for PCP prophylaxis in patients receiving
these medications until conclusive evidence is obtained.
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